In addition, HNF3γ expression rendered sensitivity of HCC cells to sorafenib treatment, implying the potential of HNF3γ as a therapeutic target for HCC (Zhou et al., 2020). The gene discussed is FOXA3; the disease is hepatocellular carcinoma.